

PROJECT ECHO®: TELE-MENTORING TO MANAGE IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS RECEIVING CANCER IMMUNOTHERAPIES

Rheumatologic Toxicities with Immune Checkpoint Inhibitors: Recommended references

Braaten TJ, Brahmer JR, Forde PM, et al. 2020. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. *Ann Rheum Dis*. 79:332-338. <https://doi.org/10.1136/annrheumdis-2019-216109>

Calabrese LH, Calabrese C, Cappelli LC. 2018. Rheumatic immune-related adverse events from cancer immunotherapy. *Nat Rev: Rheumatology*. 14: 569-579. <https://doi.org/10.1038/s41584-018-0074-9>

Cappelli L, Brahmer JR, Forde PM, et al. 2018. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. *Semin Arth Rheum*;48(3):553-557. <https://doi.org/10.1016/j.semarthrit.2018.02.011>

Esfahani K, Elkrief A, Calabrese C, et al. 2020. Moving towards personalized treatments of immune-related adverse events. *Nat Rev Clin Oncol* 17(8):504-15. <https://doi.org/10.1038/s41571-020-0352-8>

Jamal S, Hudson M, Fifi-Mah A, Ye C. 2020. Immune-related adverse events associated with cancer immunotherapy: A review for the practicing rheumatologist. *J Rheumatol* 47:166-175. <https://doi.org/10.3899/jrheum.190084>

Kostine M, Finckh A, Bingham CO, et al. 2021. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. *Ann Rheum Dis*. 80:36-48. <http://dx.doi.org/10.1136/annrheumdis-2020-217139>

Lidar M, Giat E, Garelick D, et al. 2018. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. *Autoimmune Rev*. 17(3):284-289. <https://doi.org/10.1016/j.autrev.2018.01.003>

Regan MM, Jegede OA, Mantia CM, et al. 2021. Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial. *Clin Cancer Res* 27:1-9. <https://doi.org/10.1158/1078-0432.CCR-21-2283>

Tison A, Garaud S, Chiche L, et al. 2022. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. *Nat Rev: Rheumatology* 18:641-656. <https://doi.org/10.1038/s41584-022-00841-0>

Veccia A, Kostine M, Tison A, et al. 2022. Rheumatic immune-and nonimmune-related adverse events in phase 3 trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis. *Joint Bone Spine* 89: 1-10. <https://doi.org/10.1016/j.jbspin.2022.105403>

Warnner BM, Baer AN, Lipson EJ, et al. 2019. Sicca syndrome associated with immune checkpoint inhibitor therapy. *The Oncologist* 1259-1269. <https://doi.org/10.1634/theoncologist.2018-0823>